Insight Molecular Diagnostics (IMDX) Non Operating Income (2015 - 2026)

Insight Molecular Diagnostics has disclosed Non Operating Income across 12 years of filings, most recently posting $123000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $123000.0, down 3.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$55000.0 (down 205.56% YoY), and the FY2025 annual result was $4000.0, up 150.0% from the prior year.
• Non Operating Income came in at $123000.0 for Q1 2026 at Insight Molecular Diagnostics, up from -$501000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $278000.0 in Q2 2022 to a low of -$919000.0 in Q4 2022.
• The 5-year median for Non Operating Income is $102000.0 (2024), against an average of -$43000.0.
• Peak annual rise in Non Operating Income reached 1637.5% in 2022, while the deepest fall reached 750.93% in 2022.
• Insight Molecular Diagnostics' Non Operating Income stood at -$919000.0 in 2022, then soared by 116.97% to $156000.0 in 2023, then slumped by 273.08% to -$270000.0 in 2024, then sank by 85.56% to -$501000.0 in 2025, then surged by 124.55% to $123000.0 in 2026.
• The last three Non Operating Income figures came in at $123000.0 (Q1 2026), -$501000.0 (Q4 2025), and $223000.0 (Q3 2025), per Business Quant data.